The contractor shall provide enhanced analysis of clinical and specimen-derived data on all patients seen at VA network hospitals who have a cancer diagnosis. The contractor shall furnish a robust,…

This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) to Personal Genome Diagnostics Inc., a for-profit company that provides molecular tissue testing services to federal agencies. The contract, valued at $147,900.00, requires the contractor to provide enhanced analysis of clinical and specimen-derived data on all cancer patients seen at VA network hospitals. The contractor shall furnish solutions for analyzing tissue samples obtained during clinical care using new genomic assay technology, including targeted DNA sequencing, whole exome DNA sequencing, and RNA sequencing. The products to be delivered include all sequencing data and a report of important mutations and their significance. This contract was not set aside for any special program. The award date was February 27, 2017, and the ultimate completion date was December 6, 2017.

The contractor shall provide enhanced analysis of clinical and specimen-derived data on all patients seen at VA network hospitals who have a cancer diagnosis. The contractor shall furnish a robust, scalable, dynamic, secure, innovative solutions of analyzing samples obtained during regular clinical care such as tissues from biopsy - using new genomic assay technology. The clia vendor shall provide emerging technologies to improve oncology care for all patients within the VA healthcare system. The contractor shall provide targeted sequencing of DNA fragments known to harbor mutations in cancer specimens (commonly referred to as a mutation panel). The number of DNA segments sequenced varies by the laboratory and assay performed. Mutations in the DNA can either be inferred against a laboratory `reference sequence or can be determined by sequencing of patient germ-line DNA obtained from adjacent normal tissue or peripheral blood. The contractors shall provide sequencing of the whole exome of cancer specimens, with mutations identified by comparison against a laboratory `reference sequence or germ-line DNA as described above. The contracotr shall provide sequencing of the cancer specimen RNA or `transcriptome . This strategy can be combined with either targeted or whole exome DNA sequencing. Products of the testing returned to the VA include all sequence data including raw test data (fast-Q, BAM, read quality files and variant call files) and a report of important mutations and their significance to be returned to the medical record. Mutations found in the tumor sample will be annotated so that clinicians can gain an understanding of their meaning. The laboratory shall specify how this annotation will be performed and in particular, what knowledge base will be used to generate the annotations. The contractor shall maintains an up-to-date knowledge base and must be able to update annotations of a patient report upon request. The contractor shall at all times maintain a secure environment and practice covering all protected health information (PHI).